However, lower doses like 2.5 mg become harder to measure accurately because you are working with smaller syringe volumes
Tirzepatide also beat Novos semaglutide, which is marketed as Wegovy for weight loss, in a head-to-head trial sponsored by Lilly
Pathway 2: Chronic weight management (approved November 2023, marketed as Zepbound) You qualify if you have: BMI 30 kg/m or higher (obesity), OR BMI 27 kg/m or higher (overweight) with at least one weight-related comorbid condition The weight management indication uses the brand name Zepbound rather than Mounjaro, but the active ingredient (tirzepatide) and dosing are identical
NHS access to weight management services remains limited in practice
Published pre-clinical citations on the product page include research by Sikiric et al
For researchers currently building protocols based on Phase 2 data, the Phase 3 dose selection validates the 4mg to 12mg range as the therapeutic window